

---

**5.60.051**

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2025
<b>Subsection:</b>	Central Nervous System Drugs	<b>Original Policy Date:</b>	May 14, 2021
<b>Subject:</b>	Apomorphine	<b>Page:</b>	1 of 5

---

**Last Review Date:** June 12, 2025

---

## Apomorphine

### Description

Apokyn (apomorphine) subcutaneous injection, Onapgo (apomorphine) subcutaneous injection

---

### Background

Apomorphine is a non-ergoline dopamine agonist with high in vitro binding affinity for the dopamine D<sub>4</sub> receptor, and moderate affinity for the dopamine D<sub>2</sub>, D<sub>3</sub>, and D<sub>5</sub>, and adrenergic α<sub>1</sub>D, α<sub>2</sub>B, α<sub>2</sub>C receptors. The precise mechanism of action of apomorphine as a treatment for Parkinson's disease is unknown, although it is believed to be due to stimulation of post-synaptic dopamine D<sub>2</sub>-type receptors within the caudate-putamen in the brain (1-2).

### Regulatory Status

FDA-approved indications:

- Apokyn is indicated for the acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) associated with advanced Parkinson's disease (1).
- Onapgo is indicated for the treatment of motor fluctuations in adults with advanced Parkinson's disease (2).

Apomorphine is contraindicated in patients using concomitant drugs of the 5HT<sub>3</sub> antagonist class including antiemetics (e.g., ondansetron, granisetron, dolasetron, palonosetron) and alosetron. There have been reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron (1-2).

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2025
<b>Subsection:</b>	Central Nervous System Drugs	<b>Original Policy Date:</b>	May 14, 2021
<b>Subject:</b>	Apomorphine	<b>Page:</b>	2 of 5

---

Apomorphine may cause syncope, hypotension, or orthostatic hypotension. Patients taking concomitant antihypertensive medications or vasodilators should have blood pressure monitored (1-2).

There are reports of a dose related prolongation of QTc interval after apomorphine exposure. The risks and benefits of apomorphine treatment should be considered prior to initiating treatment with apomorphine in patients with risk factors for prolonged QTc (1-2).

The safety and effectiveness of apomorphine in pediatric patients less than 18 years of age have not been established (1-2).

---

#### Related policies

Inbrija, Nourianz, Nuplazid, Tasmar

#### Policy

*This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.*

Apomorphine may be considered **medically necessary** if the conditions indicated below are met.

Apomorphine may be considered **investigational** for all other indications.

### Prior-Approval Requirements

**Age** 18 years of age or older

#### Diagnosis

Patient must have the following:

Parkinson's disease experiencing "off" episodes

**AND ALL** of the following:

1. Used in combination with carbidopa/levodopa (unless the medications are contraindicated, or patient is intolerant)

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2025
<b>Subsection:</b>	Central Nervous System Drugs	<b>Original Policy Date:</b>	May 14, 2021
<b>Subject:</b>	Apomorphine	<b>Page:</b>	3 of 5

---

2. Inadequate control of Parkinson's off episodes on maximum tolerated doses of carbidopa/levodopa therapy and adjunctive therapy (e.g., dopamine agonist, COMT inhibitor, etc.)
3. **NOT** used in combination with a 5HT3 antagonist (e.g., ondansetron, granisetron, dolasetron, palonosetron, alosetron)
4. Prescriber agrees to monitor for QTc prolongation

---

## Prior – Approval *Renewal* Requirements

**Age** 18 years of age or older

### Diagnosis

Patient must have the following:

Parkinson's disease experiencing "off" episodes

**AND ALL** of the following:

1. Improvement in Parkinson's symptoms (e.g., reduction in daily off time, improvement in motor function post-administration)
2. Used in combination with carbidopa/levodopa (unless the medications are contraindicated, or patient is intolerant)
3. **NOT** used in combination with a 5HT3 antagonist (e.g., ondansetron, granisetron, dolasetron, palonosetron, alosetron)
4. Prescriber agrees to monitor for QTc prolongation

## Policy Guidelines

### Pre - PA Allowance

None

### Prior - Approval Limits

**Duration** 6 months

---

## Prior – Approval *Renewal* Limits

**Duration** 12 months

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2025
<b>Subsection:</b>	Central Nervous System Drugs	<b>Original Policy Date:</b>	May 14, 2021
<b>Subject:</b>	Apomorphine	<b>Page:</b>	4 of 5

---

## Rationale

### Summary

Apomorphine is a non-ergoline dopamine agonist with high in vitro binding affinity for the dopamine D<sub>4</sub> receptor, and moderate affinity for the dopamine D<sub>2</sub>, D<sub>3</sub>, and D<sub>5</sub>, and adrenergic  $\alpha_1$ D,  $\alpha_2$ B,  $\alpha_2$ C receptors. The precise mechanism of action of apomorphine as a treatment for Parkinson's disease is unknown, although it is believed to be due to stimulation of post-synaptic dopamine D<sub>2</sub>-type receptors within the caudate-putamen in the brain. The safety and effectiveness of apomorphine in pediatric patients less than 18 years of age have not been established (1-2).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of apomorphine while maintaining optimal therapeutic outcomes.

### References

1. Apokyn [package insert]. Rockville, MD: MDD US Operations, LLC; June 2022.
2. Onapgo [package insert]. Rockville, MD: MDD US Operations, LLC; February 2025.

## Policy History

Date	Action
May 2021	Addition to PA
September 2021	Annual review
March 2022	Annual review and reference update
March 2023	Annual review and reference update. Changed policy number to 5.60.051
December 2023	Annual review
March 2024	Annual review
December 2024	Annual review
March 2025	Annual review
April 2025	Addition of Onapgo. Removed Kynmobi due to discontinuation
June 2025	Annual review. Per SME, changed requirement that patients only have to use with carbidopa/levodopa if not intolerant or contraindicated. Also added that patients must have inadequate control of off episodes on adjunctive therapy as well as carbidopa/levodopa

## Keywords

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2025
<b>Subsection:</b>	Central Nervous System Drugs	<b>Original Policy Date:</b>	May 14, 2021
<b>Subject:</b>	Apomorphine	<b>Page:</b>	5 of 5

---

**This policy was approved by the FEP® Pharmacy and Medical Policy Committee on June 12, 2025 and is effective on July 1, 2025.**